These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 34810377)

  • 21. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
    Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
    Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
    Cholankeril G; Kramer JR; Chu J; Yu X; Balakrishnan M; Li L; El-Serag HB; Kanwal F
    J Hepatol; 2023 Mar; 78(3):493-500. PubMed ID: 36402450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study.
    Pinyopornpanish K; Khoudari G; Saleh MA; Angkurawaranon C; Pinyopornpanish K; Mansoor E; Dasarathy S; McCullough A
    BMC Gastroenterol; 2021 Oct; 21(1):394. PubMed ID: 34674650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular Carcinoma.
    Huang YH; Chan C; Lee HW; Huang C; Chen YJ; Liu PC; Lu SN; Chuang WL; Huang JF; Yu ML; Koshiol J; Lee MH
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):960-969.e1. PubMed ID: 35124270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
    Ueno M; Takeda H; Takai A; Seno H
    World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants.
    Pais R; Lebray P; Rousseau G; Charlotte F; Esselma G; Savier E; Thabut D; Rudler M; Eyraud D; Vezinet C; Siksik JM; Vaillant JC; Hannoun L; Poynard T; Ratziu V
    Clin Gastroenterol Hepatol; 2015 May; 13(5):992-9.e2. PubMed ID: 25459558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
    Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
    Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India.
    David D; Raghavendran A; Goel A; Bharath Kumar C; Kodiatte TA; Burad D; Abraham P; Ramakrishna B; Joseph P; Ramachandran J; Eapen CE
    Indian J Gastroenterol; 2017 Sep; 36(5):373-379. PubMed ID: 28975595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
    Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
    World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.
    Polyzos SA; Chrysavgis L; Vachliotis ID; Chartampilas E; Cholongitas E
    Semin Cancer Biol; 2023 Aug; 93():20-35. PubMed ID: 37149203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
    Kramer JR; Natarajan Y; Dai J; Yu X; Li L; El-Serag HB; Kanwal F
    Hepatology; 2022 Jun; 75(6):1420-1428. PubMed ID: 34779535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
    Seif El Dahan K; Daher D; Singal AG
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NAFLD-related hepatocellular carcinoma: The growing challenge.
    Shah PA; Patil R; Harrison SA
    Hepatology; 2023 Jan; 77(1):323-338. PubMed ID: 35478412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Azuma S; Asahina Y; Kakinuma S; Azuma K; Miyoshi M; Inoue E; Tsunoda T; Sato A; Kaneko S; Nagata H; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Tomita M; Nakagawa M; Watanabe M
    Dig Dis; 2019; 37(3):247-254. PubMed ID: 30625487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease.
    Teng PC; Huang DQ; Lin TY; Noureddin M; Yang JD
    Gut Liver; 2023 Jan; 17(1):24-33. PubMed ID: 36530125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should Patients With NAFLD/NASH Be Surveyed for HCC?
    Reig M; Gambato M; Man NK; Roberts JP; Victor D; Orci LA; Toso C
    Transplantation; 2019 Jan; 103(1):39-44. PubMed ID: 30080818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Thomas JA; Kendall BJ; Dalais C; Macdonald GA; Thrift AP
    Eur J Cancer; 2022 Sep; 173():250-262. PubMed ID: 35944373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.